Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Epetraborole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epetraborole SCHEMBL3447124 | 1.00 | — | — | |
| Epetraborole SCHEMBL1498692 | 0.99 | — | — | |
| Epetraborole SCHEMBL29378846 | 0.99 | — | — | |
| Epetraborole SCHEMBL3446407 | 0.99 | — | — | |
| Epetraborole SCHEMBL1895215 | 0.99 | — | — | |
| Epetraborole SCHEMBL31673512 | 0.99 | — | — | |
| SCHEMBL3640943 | 0.95 | — | — | |
| SCHEMBL13035106 | 0.90 | — | — | |
| SCHEMBL13035381 | 0.90 | — | — | |
| Hydrochloric Acid SCHEMBL3446337 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319108-A1 | COMBINATIONS | AN2 THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | US | claimed |
| EP-4444725-A1 | NON-TUBERCULOSIS MYCOBACTERIA INFECTION TREATMENT | AN2 Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | claimed |
| EP-4444282-A1 | COMBINATIONS | AN2 Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | claimed |
| WO-2023107923-A1 | COMBINATIONS | AN2 THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | claimed |
| WO-2023107149-A1 | NON-TUBERCULOSIS MYCOBACTERIA INFECTION TREATMENT | AN2 THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | claimed |
| US-8461364-B2 | Polymorphs of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[C][1,2]oxaborol-1-OL | GLAXOSMITHKLINE LLC (US) | 2013-06-11 | — | — | US | claimed |
| EP-2378886-A1 | POLYMORPHS OF (S)-3-AMINOMETHYL-7-(3-HYDROXY-PROPOXY)-3H-BENZO[C][1,2] OXABOROL-1-OL | Anacor Pharmaceuticals, Inc. (US) | 2011-10-26 | — | — | EP | claimed |
| US-20110152217-A1 | POLYMORPHS OF (S)-3-AMINOMETHYL-7-(3-HYDROXY-PROPOXY)-3H-BENZO[C][1,2]OXABOROL-1-OL | ANACOR PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | claimed |
| WO-2010080558-A1 | POLYMORPHS OF (S)-3-AMINOMETHYL-7-(3-HYDROXY-PROPOXY)-3H-BENZO[C][1,2] OXABOROL-1-OL | ANACOR PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | WO | claimed |
| US-20250319108-A1 | COMBINATIONS | AN2 THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | US | disclosed |
| CN-120361018-A | Application of pharmaceutical composition or vaccine and small molecule compound Epetraborole hydrochloride for treating and/or inhibiting salmonella infection | 扬州大学 | 2025-07-25 | — | — | CN | disclosed |
| CN-120361018-A | Application of pharmaceutical composition or vaccine and small molecule compound Epetraborole hydrochloride for treating and/or inhibiting salmonella infection | 扬州大学 | 2025-07-25 | — | — | CN | disclosed |
| EP-4444725-A1 | NON-TUBERCULOSIS MYCOBACTERIA INFECTION TREATMENT | AN2 Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4444282-A1 | COMBINATIONS | AN2 Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-2378886-A1 | POLYMORPHS OF (S)-3-AMINOMETHYL-7-(3-HYDROXY-PROPOXY)-3H-BENZO[C][1,2] OXABOROL-1-OL | Anacor Pharmaceuticals, Inc. (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20110152217-A1 | POLYMORPHS OF (S)-3-AMINOMETHYL-7-(3-HYDROXY-PROPOXY)-3H-BENZO[C][1,2]OXABOROL-1-OL | ANACOR PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-20100292504-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-7816344-B2 | oxaboroles such as 3-[[(3S)-3-(aminomethyl)-1-hydroxy-3H-2,1-benzoxaborol-7-yl]oxy]propan-1-ol, useful for treating bacterial infections; microbiocides; antibiotics | ANACOR PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| WO-2010080558-A1 | POLYMORPHS OF (S)-3-AMINOMETHYL-7-(3-HYDROXY-PROPOXY)-3H-BENZO[C][1,2] OXABOROL-1-OL | ANACOR PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20090227541-A1 | oxaboroles such as 3-[[(3S)-3-(aminomethyl)-1-hydroxy-3H-2,1-benzoxaborol-7-yl]oxy]propan-1-ol, useful for treating bacterial infections; microbiocides; antibiotics | ANACOR PHARMACEUTICALS, INC. (US) | 2009-09-10 | — | — | US | disclosed |